Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Arcus Biosciences has raised $250.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.
Arcus Biosciences's investors include Wellington Management, Invus, Hercules Capital, Hillhouse Investment, Foresite Capital.
Arcus Biosciences is headquartered in Hayward, United States.
Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Arcus Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arcus Biosciences — Funding & Investors." VCBacked, October 21, 2026, https://www.vcbacked.co/company/arcus-biosciences. Accessed November 12, 2026.
VCBacked. (2026). Arcus Biosciences — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/arcus-biosciences
{{cite web |title=Arcus Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/arcus-biosciences |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Arcus Biosciences? Request a listing update